LioraMichalSchultzMD

Pediatric Hematology & Oncology • Palo Alto, CA

Clinical Assistant Professor, Pediatric Hematology & Oncology

Join to view full profile

Dr. Schultz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schultz's full profile

Already have an account?

Office
725 Welch Rd
Palo Alto, CA 94304
Phone+1 650-497-8000

Fax+1 650-497-8959

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2010 - 2013
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2007 - 2010
University of Toronto Faculty of MedicineClass of 2007

Certifications & Licensure

CA State Medical License 2014 - 2025
NY State Medical License 2008 - 2014
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Start of enrollment: 2020 Jan 10
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

Access to CARe: A Narrative of Real-World Medical Decision-Making to Access Chimeric Antigen Receptor (CAR) T-Cell Therapy in Children, Adolescents, and Young Adults.
Angela Steineck, Karen Chao, Anurekha G Hall, Elad Jacoby, Allison Barz Leahy
Pediatric Blood & Cancer. 2025-01-23
Pediatric relapsed/refractory ALK+ anaplastic large cell lymphoma treatment and outcomes in the targeted drug era.
Lianna J Marks, Victor Ritter, Jennifer Agrusa, Kala Y Kamdar, Julie Rivers
Blood Advances. 2025-01-22
4 citations
Intravenous and intracranial GD2-CAR T cells for H3K27Mdiffuse midline gliomas.
Michelle Monje, Jasia Mahdi, Robbie Majzner, Kristen W Yeom, Liora M Schultz
Nature. 2025-01-01

Lectures

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Higher Doses of CAR-T Therapy Bring Survival Advantage for Young Patients with Hard-to-Treat B-ALLAugust 8th, 2022
Higher CAR T-cell Dose Linked to Improved Outcomes for Younger Patients with LeukemiaAugust 8th, 2022
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
Join now to see all